Ring Nitrogen In The Pentacyclo Ring System Is Shared By Five-membered Cyclo And Six-membered Cyclo (e.g., Vincamine, Etc.) Patents (Class 514/283)
-
Patent number: 8927564Abstract: Disclosed embodiments concern polycyclic alkaloid compounds and methods for their use and synthesis. Particular embodiments concern polycyclic alkaloids having a fused, six-membered ring, while other embodiments concern polycyclic alkaloids having a fused, five-membered ring. Methods for making the polycyclic alkaloids are disclosed, as well as methods for their use as prophylactics or treatments for certain diseases. Also disclosed are pharmaceutical compositions comprising the polycyclic alkaloids and their use.Type: GrantFiled: March 7, 2013Date of Patent: January 6, 2015Assignee: Rigel Pharmaceuticals, Inc.Inventors: Dane Goff, Donald G. Payan, Sylvia Braselmann
-
Publication number: 20150004219Abstract: Liposomes with an entrapped amphipathic weak base and alkyl or aryl sulfonate are described as well as methods of making and using these liposomes.Type: ApplicationFiled: February 3, 2013Publication date: January 1, 2015Inventors: Yechezkel Barenholz, Tal Berman, Doron Friedman
-
Publication number: 20140378944Abstract: Methods and devices for delivering an agent to a solid tissue in vivo for assessment of efficacy are described. One method involves withdrawing of a needle from and injecting of the agent into the solid tissue; another method involves delivering the agent using a plurality of microdialysis probes to a solid tissue.Type: ApplicationFiled: July 10, 2014Publication date: December 25, 2014Inventors: Jason Frazier, Richard Klinghoffer, Marc Grenley
-
Publication number: 20140378409Abstract: An antitumor effect potentiator of another antitumor agent, including an acylthiourea compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient: wherein R1 represents a C1-6 alkyl group which may have a substituent, while the substituent represents any one of a hydroxyl group, a C3-10 cycloalkyl group, a C1-6 alkoxy group which may have a substituent, a C1-6 alkylamino group which may have a substituent, a C1-6 alkanoylamino group, a C1-6 alkylsulfonyl group, a C6-14 aromatic hydrocarbon group which may have a substituent, a saturated or unsaturated heterocyclic group which may have a substituent, a C1-6 alkylaminocarbonyl group which may have a substituent, a saturated or unsaturated heterocyclic carbonyl group which may have a substituent; R2 represents a fluorine atom or a chlorine atom; and R3 represents a hydrogen atom, a fluorine atom, or a chlorine atom.Type: ApplicationFiled: December 27, 2012Publication date: December 25, 2014Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Hidenori Fujita, Masanori Kato
-
Publication number: 20140378403Abstract: This invention provides compounds capable of reducing drug resistance in a subject undergoing cancer treatment, methods using the compounds, compositions, and methods for identifying such compounds.Type: ApplicationFiled: June 27, 2014Publication date: December 25, 2014Inventors: Zhenfeng Duan, Francis J. Hornicek
-
Patent number: 8916537Abstract: Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice, for example, in treatment of cancer and immune disorders.Type: GrantFiled: August 8, 2013Date of Patent: December 23, 2014Assignee: Aposense Ltd.Inventors: Ilan Ziv, Hagit Grimberg
-
Publication number: 20140371258Abstract: Provided herein are water-soluble polymer conjugates of topotecan, along with compositions comprising the conjugates and related methods of making and using the same.Type: ApplicationFiled: December 16, 2011Publication date: December 18, 2014Applicant: Nektar TherapeuticsInventors: Xuyuan Gu, Jennifer Riggs-Sauthier, Michael D. Bentley, Tacey X. Viegas
-
Publication number: 20140370121Abstract: Targeting uncontrolled cell proliferation and resistance to DNA damaging chemotherapeutics with at least one reagent has significant potential in cancer treatment. Replication Protein A, the eukaryotic single-strand (ss) DNA binding protein, is essential for genomic maintenance and stability via roles in both DNA replication and repair. Reported herein are small molecules that inhibits the in vitro, in vivo, and cellular ssDNA binding activity of RPA, thereby disrupting the eukaryotic cell cycle, inducing cytotoxicity and increasing the efficacy of chemotherapeutic agents damage DNA, and/or disrupt its replication and/or function. These results provide new insights into the mechanism of RPA-ssDNA interactions in chromosome maintenance and stability. This represents a molecularly targeted eukaryotic DNA binding inhibitor and demonstrates the utility of targeting a protein-DNA interaction as a means of studying the cell cycle and providing a therapeutic strategy for cancer treatment.Type: ApplicationFiled: August 27, 2014Publication date: December 18, 2014Inventors: John J. Turchi, Sarah Shuck
-
Patent number: 8912212Abstract: The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.Type: GrantFiled: September 27, 2013Date of Patent: December 16, 2014Assignee: BIND Therapeutics, Inc.Inventors: Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
-
Publication number: 20140363522Abstract: The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins.Type: ApplicationFiled: May 13, 2014Publication date: December 11, 2014Inventors: Ernst LENGYEL, Kristin NIEMAN, Hilary KENNY
-
Publication number: 20140363491Abstract: The present disclosure provides lipid-containing compositions, including targeted liposomes encapsulating drug, and pharmaceutical formulations thereof, as well as methods for the making and using the lipid-containing compositions, including the use of the targeted liposomes in the treatment of cancer and other diseases.Type: ApplicationFiled: May 9, 2014Publication date: December 11, 2014Applicant: Mebiopharm Co., Ltd.Inventors: Kazushi OKADA, Tadayuki IBUKI, Donghyun KIM, Tadashi FUJISAWA
-
Publication number: 20140357659Abstract: Provided herein are methods directed to the prediction and early assessment of the efficacy of cancer treatment regimens, in particular in patients undergoing therapy with a DNA-damaging chemotherapeutic agent, by determining expression levels of certain proteins found to be useful as biomarkers in circulating tumor cells obtained from the patient both prior to and post-treatment.Type: ApplicationFiled: May 30, 2014Publication date: December 4, 2014Applicant: NEKTAR THERAPEUTICSInventors: Ute Hoch, Christine Taylor Brew, Stephen David Harrison, Dennis G. Fry, Darin W. Davis
-
Publication number: 20140348854Abstract: The invention provides compositions and methods for utilizing human epididymal secretory protein E4 (HE4) in the prevention and treatment of cancer and other human diseases.Type: ApplicationFiled: June 6, 2012Publication date: November 27, 2014Applicant: WOMEN & INFANTS' HOSPITAL OF RHODE ISLANDInventors: Richard G. Moore, Rakesh K. Singh
-
Publication number: 20140348958Abstract: A compound of formula (I), a positional or structural isomer thereof, or a pharmaceutically acceptable base addition salt or acid addition salt thereof, use thereof as a medicament, in particular an anticancer medicament.Type: ApplicationFiled: September 12, 2012Publication date: November 27, 2014Inventors: Pierre Chalard, Florence Caldefie-Chezet, Laetitia Delort, Kirti Patel
-
Publication number: 20140343088Abstract: Disclosed is a trolox derivative-modified fat-soluble anti-cancer pharmaceutical compound having a structure as represented by formula I or II. An active moiety of the anti-cancer pharmaceutical compound, camptothecin or a camptothecin derivative, is covalently bonded to a lipophilic moiety, a trolox ester or a trolox amide, by a linking group to form the fat-soluble anti-cancer pharmaceutical compound. Also disclosed are a preparation, preparing method and use of the pharmaceutical compound.Type: ApplicationFiled: October 18, 2012Publication date: November 20, 2014Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.Inventor: Yuehua Zhang
-
Publication number: 20140341849Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Inventors: Deng PAN, Masha Kocherginsky, Suzanne D. Conzen
-
Publication number: 20140335191Abstract: Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Remarkably, clinical studies have proven that contemplated compositions achieved the desired effects using a minimal number of active ingredients at or near threshold active dosages, wherein such compositions almost exclusively comprise huperzine A, vinpocetine or rhodiola, and acetyl-L-carnitine, and optionally further include alpha lipoic acid, rhodiola, and biotin.Type: ApplicationFiled: July 29, 2014Publication date: November 13, 2014Inventor: JOSH REYNOLDS
-
Patent number: 8883775Abstract: The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.Type: GrantFiled: October 25, 2011Date of Patent: November 11, 2014Assignee: Cascade Prodrug Inc.Inventors: John G. Curd, John F. W. Keana, Alshad S. Lalani, Paul B. Westberg, Bradford Goodwin, W. David Henner
-
Patent number: 8877715Abstract: There is provided a series of novel neuropeptide Y-cytotoxic conjugates, compositions comprising the same, and methods relating to their therapeutic use for the treatment of disease or condition states associated with aberrant or undesirable proliferation of cells that express NPY-Y1 receptors.Type: GrantFiled: August 18, 2011Date of Patent: November 4, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Kevin Zhou, Daniel B. Deoliveira
-
Publication number: 20140323513Abstract: Disclosed are compound for targeting chemotherapeutic agents to mammalian mitochondria. Also disclosed are monoamine oxidase-specific compositions, and methods of using them for the selective therapy of mammalian cancers, and in particular, in the treatment of human gliomas. Also disclosed are methods employing the novel targeted chemotherapeutics with one or more conventional anti-cancer therapies, including, for example, radiotherapy, or multi-drug regimens.Type: ApplicationFiled: April 30, 2014Publication date: October 30, 2014Inventors: David S. Baskin, Martyn Alun Sharpe
-
Publication number: 20140323514Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: ApplicationFiled: July 3, 2014Publication date: October 30, 2014Inventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
-
Patent number: 8871253Abstract: A liposome comprising bilayer and inner water phase is disclosed. Said inner water phase contains sulfobutyl ether cyclodextrin and active compound. Said sulfobutyl ether cyclodextrin is sulfobutyl ether ?-cyclodextrin, sulfobutyl ether ?-cyclodextrin, or sulfobutyl ether ?-cyclodextrin.Type: GrantFiled: October 26, 2010Date of Patent: October 28, 2014Assignee: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.Inventors: Chunlei Li, Lan Zhang, Caixia Wang, Li Zhang, Dongmin Shen, Yanhui Li, Xian Xiu, Min Liang, Yongfeng Li
-
Publication number: 20140315893Abstract: The invention provides 1,4-dihydropyridine derivatives of formula (I) wherein R1 is optionally substituted C6-24aryl group or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and combinations thereof; R2 and R3 are independently hydrogen or C1-6alkyl group; R4 and R5 are independently hydrogen, C1-6alkyl group optionally substituted with amino, mono- or di(C1-6alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 N, O, S heteroatoms and optionally substituted with C1-6alkyl group or C1-6 alkoxy group; R6 is C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-6alkyl or arylC1-6alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disorder mediType: ApplicationFiled: November 22, 2012Publication date: October 23, 2014Inventors: Ferenc Fülöp, László Vígh, Zsolt Török, Botond Penke, Ibolya Horváth, Gábor Balogh, Sándor Bernáth, Ákos Hunya
-
Publication number: 20140314664Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with water insoluble or poorly water soluble pharmaceutically active agents (PAA). The aggregates formed are specifically induced by interaction of PAA and homopolymer and are different from aggregates that are formed by the polymer alone in the absence of the PAA or by the PAA alone in the absence of the polymer. Such aggregates can be used to improve drug solubility, stability, delivery and efficacy.Type: ApplicationFiled: January 6, 2012Publication date: October 23, 2014Applicant: ANP Technologies, Inc.Inventors: Dujie Qin, Ray Yin, Jing Pan, Yubei Zhang
-
Publication number: 20140314750Abstract: Described herein are methods of predicting the risk of developing ovarian cancer recurrence of a subject comprising the steps of detecting the expression levels of at least four of the six genes selected from the group consisting of AKT2, KRAS, RAC1, CALM3, RPS6KA2 and YWHAB or the gene products thereof, wherein the presence of increased expression levels of the genes or the gene products is predictive of the increased risk of developing ovarian cancer recurrence in the subject. Kits for practicing the methods are also disclosed.Type: ApplicationFiled: April 11, 2014Publication date: October 23, 2014Applicant: Wisconsin Alumni Research FoundationInventors: Christina Kendziorski Newton, Kevin Hasegawa Eng
-
Publication number: 20140308370Abstract: Compositions and methods for determining circulating biomolecules before, during, and/or after treatment of a patient with an anti-cancer or anti-tumor drug (or putative drug) are described. Methods of treatments based on the compositions and methods described herein are also provided. Noninvasive methods and kits are provided for assessing the efficacy of an anti-cancer therapy for killing or damaging cancer cells. Embodiments are used to determine the cancer-killing efficacy of an anti-cancer drug in a patient, to optimize the selection of an anti-cancer drug for treatment of a patient, to adjust the dosage of an anti-cancer drug for treatment of a particular cancer in a patient and for identifying useful anti-cancer therapeutics for any one particular type of cancer.Type: ApplicationFiled: April 15, 2014Publication date: October 16, 2014Inventors: David Frendewey, Gavin Thurston, George D. Yancopoulos, Matthew Koss, Gustavo Droguett
-
Publication number: 20140308336Abstract: Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 ?m to about 1000 ?m, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.Type: ApplicationFiled: April 10, 2014Publication date: October 16, 2014Applicants: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Laura Indolfi, Elazer R. Edelman, Robert S. Langer, Jeffrey W. Clark, David T. Ting, Cristina Rosa Annamaria Ferrone, Matteo Ligorio
-
Publication number: 20140302173Abstract: A method for treating side effects of anticancer agent includes administering to a subject in need thereof a prophylactic and/or therapeutic agent containing a therapeutically effective amount of a compound shown by the following Formula (1): R1—NHCH2COCH2CH2COOR2 ??(I) wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group, or a salt thereof.Type: ApplicationFiled: October 5, 2012Publication date: October 9, 2014Applicants: NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITY, SBI PHARMACEUTICALS CO., LTD.Inventors: Tohru Tanaka, Kyoko Tsuchiya, Masahiro Ishizuka, Motowo Nakajima, Hitoshi Nakagawa, Taro Shuin, Keiji Inoue, Hideo Fukuhara, Masayuki Tsuda, Mutsuo Furihata
-
Patent number: 8853233Abstract: A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma and epidermoid skin carcinoma.Type: GrantFiled: February 7, 2008Date of Patent: October 7, 2014Assignees: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Istituto Nazionale per lo Studio e la Cura dei TumoriInventors: Claudio Pisano, Loredana Vesci, Franco Zunino
-
Patent number: 8853151Abstract: The present invention provides methods, compositions and applications for efficient, site-specific drug delivery using pro-drug complexes comprising one or more functional groups (e.g., imaging agents, targeting agents, and trigger agents) conjugated with a therapeutic agent (e.g., a chemotherapeutic agent), methods of synthesizing the same, as well as systems and methods utilizing the therapeutic and diagnostic compositions (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, etc.))). Trigger agents include an indolequinone; attachment groups include a triazole ring; and therapeutic agents include camptothecin.Type: GrantFiled: June 30, 2010Date of Patent: October 7, 2014Assignee: The Regents of the University of MichiganInventors: James R. Baker, Jr., Baohua M. Huang, Thommey P. Thomas
-
Publication number: 20140294818Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing a PGAM1 mediated condition such as cancer or tumor growth comprising administering an effective amount of PGAM1 inhibitor, for example, an anthracene-9,10-dione derivative to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, head and neck cancer, and leukemia, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.Type: ApplicationFiled: October 11, 2012Publication date: October 2, 2014Applicant: EMORY UNIVERSITYInventors: Jing Chen, Taro Hitosugi, Sumin Kang
-
Publication number: 20140294973Abstract: The present invention provides a pharmaceutical composition comprising at least one hydrophobic camptothecin derivative or a pharmaceutically acceptable salt of said derivative and a polyethylene glycol (PEG) conjugated phospholipid. Also provided is a method to inhibit cancer cells in a subject in need thereof by administering the pharmaceutical composition of the present invention.Type: ApplicationFiled: November 2, 2012Publication date: October 2, 2014Inventors: Pei Kan, ChiaHung Hung, Kee-lung Hong, Yun-Long Tseng, Yun-Hsu Chan
-
Publication number: 20140296278Abstract: Provided herein are compositions for lowering intracellular pH in a cell or population of cells from a subject comprising contacting the cell or population of cells with a therapeutically effective amount of 5-nonyloxytryptamine or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivatives thereof. These compounds are useful for acidification of cells, including cancer cells, which induces apoptosis and cell necrosis. Methods of use of these compounds, including in pharmaceutical compositions in conjunction with other biologically active agents, in treatment of cancers, including glioblastoma and related neuronal cancers are also included.Type: ApplicationFiled: October 25, 2012Publication date: October 2, 2014Inventor: Eli Eliyahu Bar
-
Publication number: 20140286938Abstract: The present invention relates to spiroketal compounds that are useful in methods of treating or preventing protozoal infections, parasitic infections, bacterial infections, cell proliferative disorders and anti inflammatory disorders. The spiroketal compounds are also useful as immunosuppressive agents, and also in methods of controlling pests.Type: ApplicationFiled: March 21, 2014Publication date: September 25, 2014Applicant: EcoBiotics LtdInventors: Paul Warren Reddell, Victoria Anne Gordon
-
Publication number: 20140287063Abstract: Provided are methods of determining a response to a chemotherapeutic agent in a subject with ovarian cancer, comprising: determining a RNA integrity value of a sample comprising ovarian cancer cell RNA from the subject after the subject has received one or more doses of the chemotherapeutic agent; wherein a low RNA integrity value and/or RNA degradation of the cancer cell RNA is indicative that the cancer is responding to the chemotherapeutic agent and/or a high RNA integrity value and/or stable RNA integrity of the ovarian cancer cell RNA is indicative that the cancer is resistant to the chemotherapeutic agent.Type: ApplicationFiled: August 10, 2011Publication date: September 25, 2014Applicants: RNA DIAGNOSTICS INC., LAURENTIAN UNIVERSITY OF SUDBURYInventors: Amadeo Mark Parissenti, Baoqing Guo, Kenneth Pritzker, Laura Pritzker
-
Patent number: 8835482Abstract: The present invention is concerned with novel substituted indazole and aza-indazole derivatives of Formula (I) wherein R1, R2, R3, R4, Y, A1, A2, A3, A4, X1, X2, X3 and Het1 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: May 5, 2010Date of Patent: September 16, 2014Assignees: Janssen Pharmaceuticals, Inc., Cellzome LimitedInventors: François Paul Bischoff, Henricus Jacobus Maria Gijsen, Serge Maria Aloysius Pieters, Garrett Berlond Minne
-
Publication number: 20140255348Abstract: A pharmaceutical combination comprising a topoisomerase I inhibitor, and an Hsp90 inhibitor according to the following formulae (I) (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein.Type: ApplicationFiled: November 1, 2012Publication date: September 11, 2014Applicant: SYNTA PHARMACEUTICALS CORP.Inventor: David Proia
-
Publication number: 20140256619Abstract: The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) wherein: (i) R1 is chosen from the group constituted of —CH(CH3)2, —CH(CH3)CH2CH3, or cyclohexyle, (ii) X represents —CH2CH2—, or —CH?CH—, (iii) R2 is chosen from the group constituted of or —OH group, (iv) R3 is OH or NOH, (v) represents a single bond when R3 is OH, or a double bond when R3 is NOH, as an inhibitor of a membrane-bound protein which transports exogenous compounds out of target cells.Type: ApplicationFiled: October 18, 2012Publication date: September 11, 2014Inventors: Anne Lespine, Roger Prichard, Cecile Menez
-
Publication number: 20140255502Abstract: A pharmaceutical composition is provided. The pharmaceutical composition includes a nanoparticle, a shell and a drug, wherein the nanoparticle has an outer surface and the drug is mixed with the shell and is formed on the outer surface.Type: ApplicationFiled: September 25, 2013Publication date: September 11, 2014Applicant: National Chiao Tung UniversityInventors: San-Yuan Chen, Wei-Ming Li
-
Patent number: 8829021Abstract: A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of pediatric tumors such as for examplerhabdomyosarcoma, primitive neuroectodermal tumors (PNET) and neuroblastoma.Type: GrantFiled: July 3, 2008Date of Patent: September 9, 2014Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Claudio Pisano, Loredana Vesci, Paolo Carminati
-
Publication number: 20140249203Abstract: Described herein are carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a boronic acid, configured to present the polymer containing a boronic acid to an environment external to the nanoparticle. Targeted versions of the described nanoparticles are also described, as are related compositions, methods and systems.Type: ApplicationFiled: March 1, 2013Publication date: September 4, 2014Inventors: Mark E. Davis, Han Han
-
Patent number: 8822491Abstract: The present invention provides compounds (such as compounds of formula I-a) that induce ? globin expression and pharmaceutical compositions thereof. Such compounds may have beneficial therapeutic effects. Compounds and compositions described herein may be used to treat hemoglobinopathies such as ?-thalassemia and sickle cell anemia.Type: GrantFiled: January 3, 2012Date of Patent: September 2, 2014Assignee: Academia SinicaInventors: Che-kun James Shen, Yu-Chi Chou
-
Publication number: 20140242026Abstract: Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.Type: ApplicationFiled: May 8, 2014Publication date: August 28, 2014Inventors: Robert Shalwitz, Kevin Gene Peters
-
Publication number: 20140234295Abstract: Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.Type: ApplicationFiled: November 1, 2011Publication date: August 21, 2014Applicant: MARSHALL EDWARDS, INC.Inventors: George Jeoffreys, Alison Johnson, Andrew Heaton, Ofir Moreno
-
Patent number: 8809362Abstract: To provide a marker for determining sensitivity of a patient to an anti-cancer agent, and novel cancer therapeutic means employing the marker. The marker for determining sensitivity to an anti-cancer agent is formed of one or more substances selected from the group consisting of a substance or a fragment thereof detected as an anion at m/z of 149.05 to 149.06, a substance or a fragment thereof detected as an anion at m/z of 152.99 to 153.00, a substance or a fragment thereof detected as a cation at m/z of 724.34 to 724.35, the peaks being determined by means of a mass spectrometer, glycerol 3-phosphate, dihydrobiopterin, GABA, lactic acid, asparagine, aspartic acid, 2-methylbutyroylcarnitine, 1-methyladenosine, and glutathione, and a substance involved in a metabolic pathway of any of these substances.Type: GrantFiled: October 29, 2010Date of Patent: August 19, 2014Assignees: Keio University, Kabushiki Kaisha Yakult HonshaInventors: Yusuke Tanigawara, Tetsuya Suzuki, Akito Nishimuta, Shinji Sugimoto, Yoshiaki Igarashi
-
Patent number: 8802240Abstract: Disclosed are methods of increasing the chemosensitivity of normal and/or chemoresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof. Also disclosed are methods of increasing radiosensitivity of normal and/or radioresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof.Type: GrantFiled: January 6, 2012Date of Patent: August 12, 2014Assignee: Nanopharmaceuticals LLCInventors: Paul J. Davis, Shaker A. Mousa
-
Patent number: 8802692Abstract: This invention is based on the discovery that the administration of a sphingosine-1-phosphate receptor antagonist (S1P) and at least one chemotherapeutic agent selected from the the group of antimicrotubule agents provides an unexpectedly superior treatment for cancer. Antimicrobial agents such as the taxane compounds are known in the art, for example, paclitaxel (available as TAXOL® from Bristol-Myers Squibb, Princeton, N.J.), docetaxel (available as TAXOTERE® from Sanofi-aventis, Bridgewater, N.J.) and the like and other compounds that act as antimicrotubule agents, such as Vincristine (ONCOVIN®, VINCASAR PFS®, VCR), Vinblastin (VELBAN®, VELSAR®) and Vinorelbine, and similar compounds. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one sphingosine-1-phosphate 1 (S1P1R) receptor antagonists, and at least one antimicrotubule agent.Type: GrantFiled: October 16, 2009Date of Patent: August 12, 2014Assignee: Exelixis, Inc.Inventors: Geetha Shankar, Frauke Bentzien, Peter Lamb, David Matthews
-
Publication number: 20140220112Abstract: Sparingly water-soluble agents can be formulated as cyclodextrin complexes, however, these water-soluble drug-cyclodextrin complexes dissociate when the complex is administered into patients. The dilution of the complex in the patient leads to the drug being released from the complex, so the drug is not effectively targeted. In contrast, drugs encapsulated in the aqueous core of a lipid vesicles are not released when the liposome is diluted in blood. This invention describes compositions and methods whereby cyclodextrin or polyanionic beta-cyclodextrin drug-complexes are mixed with a preformed liposome containing the amine salts of an acidic compound. This results in the drug cyclodextrin complex being transferred into the liposome where it is stably retained. The liposome-encapsulated drug can then be injected into a patient.Type: ApplicationFiled: February 3, 2014Publication date: August 7, 2014Inventors: Francis C. SZOKA, JR., Charles O. Noble, Mark E. Hayes
-
Publication number: 20140212480Abstract: Described herein are pharmaceutical compositions according to aspects of the present invention which include one or more hydrophilic antineoplastic chemotherapeutics, such as vinca alkyloid antineoplastic chemotherapeutics, encapsulated in ceramide anionic liposomes. Methods of treatment of a subject having cancer using the pharmaceutical compositions are described, along with methods of making ceramide anionic liposomes which encapsulate one or more hydrophilic antineoplastic chemotherapeutics in the aqueous interior of the ceramide anionic liposomes.Type: ApplicationFiled: April 3, 2014Publication date: July 31, 2014Applicant: The Penn State Research FoundationInventors: Mark Kester, Sriram S. Shanmugavelandy, Todd Fox
-
Publication number: 20140205596Abstract: The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer.Type: ApplicationFiled: June 22, 2012Publication date: July 24, 2014Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng Li, Youyi Peng, John Tomesch, Lawrence P. Wennogle, Qiang Zhang